Literature DB >> 9017618

Biochemical markers for non-invasive diagnosis of hyperparathyroid bone disease and adynamic bone in patients on haemodialysis.

A Gerakis1, A J Hutchison, T Apostolou, A J Freemont, A Billis.   

Abstract

UNLABELLED: The diagnostic and predictive value of serum intact parathyroid hormone (iPTH) and osteocalcin (bone Gla protein, BGP), alone or in combination, have been examined in only a small number of haemodialysis patients.
METHODS: We studied prospectively 114 patients (46 women, 68 men; mean age 52 +/- 12 years) on regular haemodialysis for a mean of 55 (6-185) months. All patients underwent labelled transiliac bone biopsy, and serum levels of iPTH, BGP and alkaline phosphatase were determined.
RESULTS: Seventy-one patients (62%) showed histological findings of hyperparathyroid bone disease, 24 (21%) mixed bone disease, six (5.5%) osteomalacia and 13 (11.5%) adynamic bone. Bone aluminium deposition over more than 25% of the trabecular bone interface was found in 66 patients (58%). Serum iPTH and BGP correlated with the majority of histomorphometric indices of bone formation, mineralization and resorption (r > 0.5, P < 0.01). iPTH levels > or = 200 pg/ml and BGP > or = 50 ng/ml were found to be indicative of hyperparathyroid bone disease, whilst iPTH levels < 65 pg/ml and BGP < 20 ng/ml were indicative of adynamic bone. However, the positive predictive value of these indices was limited (less than 80%), although their negative predictive value, especially when used in combination, was good (more than 90%) and the exclusion of hyperparathyroid bone disease and adynamic bone was possible. The diagnostic and predictive value of these bone markers were improved when patients with bone aluminium deposition were excluded.
CONCLUSIONS: Diagnosis of hyperparathyroid bone disease and adynamic bone is difficult on the basis of iPTH and BGP, especially when bone aluminium deposition is prevalent. However, using these bone markers, preferably in combination, the exclusion of these lesions is feasible.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9017618     DOI: 10.1093/oxfordjournals.ndt.a027210

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

1.  Bone mineral density and parathyroid function in patients on maintenance hemodialysis.

Authors:  Cs Ambrus; Cs Almasi; K Berta; Gy Deak; A Marton; M Zs Molnar; Zs Nemeth; Cs Horvath; P Lakatos; M Szathmari; I Mucsi
Journal:  Int Urol Nephrol       Date:  2010-01-21       Impact factor: 2.370

Review 2.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

Review 3.  Treatment of metabolic bone disease in patients with chronic renal disease: a perspective for rheumatologists.

Authors:  Paul D Miller
Journal:  Curr Rheumatol Rep       Date:  2005-03       Impact factor: 4.592

4.  [Oral calcitriol pulse therapy in hemodialysis patients. Effects on histomorphometry of bone in renal hyperparathyroidism].

Authors:  H Sperschneider; K Humbsch; K Abendroth
Journal:  Med Klin (Munich)       Date:  1997-10-15

Review 5.  Osteoporosis in patients with diabetes after kidney transplantation.

Authors:  Elvira O Gosmanova; Aidar R Gosmanov
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

6.  Bone histomorphometry in a long-term hemodialysis patient with hypoparathyroidism and sarcoidosis.

Authors:  K Sumida; Y Ubara; J Hoshino; N Hayami; T Suwabe; R Hiramatsu; E Hasegawa; M Yamanouchi; N Sawa; T Fujii; K Takaichi
Journal:  Osteoporos Int       Date:  2014-12-13       Impact factor: 4.507

Review 7.  Treatment of osteoporosis in chronic kidney disease and end-stage renal disease.

Authors:  Paul D Miller
Journal:  Curr Osteoporos Rep       Date:  2005-03       Impact factor: 5.096

Review 8.  The role of bone biopsy in patients with chronic renal failure.

Authors:  Paul D Miller
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

9.  Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.

Authors:  K Sumida; Y Ubara; J Hoshino; K Mise; N Hayami; T Suwabe; M Kawada; A Imafuku; R Hiramatsu; E Hasegawa; M Yamanouchi; N Sawa; K Takaichi
Journal:  Osteoporos Int       Date:  2015-11-02       Impact factor: 4.507

Review 10.  Bone mineral density in patients on maintenance dialysis.

Authors:  Csaba Ambrus; Adrienn Marton; Zsofia Klara Nemeth; Istvan Mucsi
Journal:  Int Urol Nephrol       Date:  2009-12-29       Impact factor: 2.370

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.